2024-03-29T14:51:18Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02016874
2022-02-22T07:17:58Z
1642838163960:1642838198944:1642838199408:1642838230007
1642838403551:1642838412624
[総説]臨床膵島移植と細胞処理センター
[Review]Clinical islet transplantation and cell processing center
野口, 洋文
Noguchi, Hirofumi
open access
琉球医学会
islet transplantation
islet isolation
cell processing center (CPC)
current Good Manufacturing Practice (cGMP)
Type 1 diabetes mellitus is an autoimmune disease characterized by the destruction of the islets of Langerhans cells, which produce insulin. Pancreatic islet transplantation is a promising option for the treatment of patients with type 1 diabetes who experience hypoglycemic unawareness despite receiving maximal care. Following the successful demonstration of the Edmonton protocol, more than 1,000 patients with type 1 diabetes have been treated at more than 50 institutions using islet transplantation. Clinical islet isolation is currently performed in a Good Manufacturing Practice (cGMP) islet processing facility, called a Cell Processing Center (CPC). The protocol for islet isolation has shown significant advancements on several fronts, including pancreatic ductal protection, improvements in pancreas preservation systems, a new islet purification method and culture/preservation of isolated islets. In this article, we review the current state of research regarding pancreatic islet transplantation.
論文
琉球医学会
jpn
journal article
VoR
http://hdl.handle.net/20.500.12000/0002016874
https://u-ryukyu.repo.nii.ac.jp/records/2016874
AN10369445
琉球医学会誌 = Ryukyu Medical Journal
34
1・2
9
12
https://u-ryukyu.repo.nii.ac.jp/record/2016874/files/v34p9.pdf